

Lipoprotein(a) and Its Association with Coronary Heart Disease: Data from a Large Cohort in the Russian
https://doi.org/10.18087/cardio.2025.4.n2866
Abstract
Aim To study the distribution of lipoprotein(a) [Lp(a)] concentrations in a large sample of the adult population of the Russian Federation depending on gender and age, and the Lp(a) association with the incidence of ischemic heart disease (IHD).
Material and methods Cross-analysis of electronic medical records of patients older than 18 years managed in the MEDSI Group of Companies as a part of primary and secondary prevention.
Results Among 73,763 patients, the mean age was 45 [37; 56] years, 57.3% were women. The median Lp(a) concentration was 11 [6.0; 32.0] mg/dl. The median Lp(a) concentration in women was higher than in men, 12.0 and 10.5 mg/dl, respectively (p<0.0001). Hyperlipoproteinemia(a) (Lp(a) >30 mg/dl) was diagnosed in 26% (n=19,188) of patients (95% confidence interval (CI): 25.7-26.3), statistically significant association with IHD was observed over the entire range of elevated Lp(a) concentrations (p<0.001). Extremely high Lp(a) concentrations exceeding 180 mg/dl were detected in 852 (1.2%) of patients, and 210 of them were diagnosed with IHD. Logistic regression analysis confirmed a significant association between Lp(a) concentrations and IHD (odds ratio (OR) 1.006; 95% CI 1.003-1.008; p<0.001). With an increase in Lp(a) by 1 mg/dl, the likelihood of having IHD increased by 1.006 times. With Lp(a) >50 mg/dL, the likelihood of IHD increased by 1.32 times (OR 1.320; 95% CI 1.254-1.390; p<0.001), with Lp(a) >180 mg/dL, by 2.06 times (OR 2.058; 95% CI 1.758-2.408), and with Lp(a) 30-50 mg/dL, by 1.1 times (OR 1.100; 95% CI 1.017-1.188; p=0.016).
Conclusion Every fourth person has an elevated Lp(a) concentration, which determines a high risk of developing cardiovascular diseases. Taking into account the accumulated data, early assessment of the Lp(a) concentration is necessary for all adults.
Keywords
About the Authors
G. A. KonovalovRussian Federation
Chairman of the Scientific Council of the MEDSI Group of Companies, Head of the Center for Diagnostics and Innovative Medical Technologies at the Clinical Diagnostic, Professor, Doctor of Medical Sciences
Z. I. Khutaeva
Russian Federation
Cardiologist-lipidologist at the Cardiology Department
M. B. Mukhtarov
Russian Federation
Director of the Data Management Department «MEDSI Digital» LLC
V. L. Averkiev
Russian Federation
Head of the Department of Extracorporeal Treatment Methods at the Center of Diagnostics and Innovative Medical Technologies, PhD in Medicine
O. N. Korneeva
Russian Federation
Cardiologist, Head of the Lipidology Office, PhD in Medicine
O. S. Kalacheva
Russian Federation
Medical Director Deputy of MEDSI Laboratory Diagnostics.
V. S. Rabicheva
Russian Federation
Transfusiologist at the Department of Extracorporeal Methods of Treatment
References
1. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022;43(39):3925–46. DOI: 10.1093/eurheartj/ehac361
2. Amiri M, Raeisi-Dehkordi H, Verkaar AJCF, Wu Y, Van Westing AC, Berk KA et al. Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis. European Journal of Epidemiology. 2023;38(5):485–99. DOI: 10.1007/s10654-022-00956-4
3. Qin T, Ma T-Y, Huang K, Lu S-J, Zhong J-H, Li J-J. Lipoprotein (a) – Related Inflammatory Imbalance: A Novel Horizon for the Development of Atherosclerosis. Current Atherosclerosis Reports. 2024;26(8):383–94. DOI: 10.1007/s11883-024-01215-5
4. Simony SB, Mortensen MB, Langsted A, Afzal S, Kamstrup PR, Nordestgaard BG. Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study. Atherosclerosis. 2022;355:76–82. DOI: 10.1016/j.atherosclerosis. 2022.06.1023
5. Masson W, Barbagelata L, Corral P, Nogueira JP, Lavalle-Cobo A, Belardo A. Relationship Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Postmenopausal Women: A Systematic Review. Current Problems in Cardiology. 2023;48(4):101589. DOI: 10.1016/j.cpcardiol.2023.101589
6. Ezhov M.V., Kukharchuk V.V., Sergienko I.V., Alieva A.S., Antsiferov M.B., Ansheles A.A. et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):250–97. DOI: 10.15829/1560-4071-2023-5471
7. Velilla TA, Guijarro C, Ruiz RC, Piñero MR, Francisco Valderrama Marcos J, López AMB et al. Consensus document for lipid profile determination and reporting in Spanish clinical laboratories. What parameters should be included in a basic lipid profile? Nefrología (English Edition). 2023;43(4):474–83. DOI: 10.1016/j.nefroe.2023.08.002
8. Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S et al. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arteriosclerosis, Thrombosis, and Vascular Biology. 2021;41(1):465– 74. DOI: 10.1161/ATVBAHA.120.315291
9. Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. Journal of Clinical Lipidology. 2024;18(3):e308–19. DOI: 10.1016/j.jacl.2024.03.001
10. Björnson E, Adiels M, Taskinen M-R, Burgess S, Chapman MJ, Packard CJ et al. Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis. Journal of the American College of Cardiology. 2024;83(3):385–95. DOI: 10.1016/j.jacc.2023.10.039
11. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. JAMA. 2009;301(22):2331–9. DOI: 10.1001/jama.2009.801
12. Correction to: Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity. European Journal of Preventive Cardiology. 2024;31(7):915. DOI: 10.1093/eurjpc/zwae104
13. Shiyovich A, Berman AN, Besser SA, Biery DW, Kaur G, Divakaran S et al. Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry. Journal of the American Heart Association. 2024;13(10):e034493. DOI: 10.1161/JAHA.123.034493
14. Lu J, Wang Z, Zhang J, Jiao F, Zou C, Han L et al. Causal association of blood lipids with all-cause and cause-specific mortality risk: a Mendelian randomization study. Journal of Lipid Research. 2024;65(4):100528. DOI: 10.1016/j.jlr.2024.100528
15. Tsimikas S, Marcovina SM. Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds. Journal of the American College of Cardiology. 2022;80(9):934–46. DOI: 10.1016/j.jacc.2022.06.019
16. Mehta A, Jain V, Saeed A, Saseen JJ, Gulati M, Ballantyne CM et al. Lipoprotein(a) and ethnicities. Atherosclerosis. 2022;349:42–52. DOI: 10.1016/j.atherosclerosis.2022.04.005
17. Wong ND, Fan W, Hu X, Ballantyne C, Hoodgeveen RC, Tsai MY et al. Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort. Journal of the American College of Cardiology. 2024;83(16):1511–25. DOI: 10.1016/j.jacc.2024.02.031
18. Brar S, Huang Q, Yan X, Dudum R, Jose P, Sarraju A et al. Factors Associated with Lipoprotein(a) Testing Among Multiethnic Individuals. Journal of General Internal Medicine. 2025;40(4):756–63. DOI: 10.1007/s11606-024-09126-6
19. Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF et al. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiology. 2018;3(7):619–27. DOI: 10.1001/jamacardio.2018.1470
20. Ezhov M.V., Shalnova S.A., Yarovaya E.B., Kutsenko V.A., Evstifeeva S.E., Metelskaya V.A. et al. Lipoprotein(a) in an adult sample from the Russianpopulation: distribution and associationwith atherosclerotic cardiovascular diseases. Archives of Medical Science. 2021;19(4):995–1002. DOI: 10.5114/aoms/131089
21. Yang P, Tang L, Guo H, He Y, Qin Y, Yan L et al. Prevalence of Lipoprotein( a) Measurement and its Association with Arteriosclerosis in Asymptomatic Individuals in China. Journal of Atherosclerosis and Thrombosis. 2024;65214. [Epub ahead of print]. DOI: 10.5551/jat.65214
22. Shah NP, Mulder H, Lydon E, Chiswell K, Hu X, Lampron Z et al. Lipoprotein (a) Testing in Patients With Atherosclerotic Cardiovascular Disease in 5 Large US Health Systems. Journal of the American Heart Association. 2024;13(21):e035610. DOI: 10.1161/JAHA.124.035610
23. Panza GA, Blazek O, Tortora J, Saucier S, Fernandez AB. Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease. Journal of Clinical Lipidology. 2023;17(6):748–55. DOI: 10.1016/j.jacl.2023.09.016
24. Safarova MS, Ezhov MV, Afanasieva OI, Matchin YG, Atanesyan RV, Adamova IYu et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atherosclerosis Supplements. 2013;14(1):93–9. DOI: 10.1016/j.atherosclerosissup.2012.10.015
25. Kronenberg F. Lipoprotein(a): from Causality to Treatment. Current Atherosclerosis Reports. 2024;26(3):75–82. DOI: 10.1007/s11883-024-01187-6
Review
For citations:
Konovalov G.A., Khutaeva Z.I., Mukhtarov M.B., Averkiev V.L., Korneeva O.N., Kalacheva O.S., Rabicheva V.S. Lipoprotein(a) and Its Association with Coronary Heart Disease: Data from a Large Cohort in the Russian. Kardiologiia. 2025;65(4):3-9. (In Russ.) https://doi.org/10.18087/cardio.2025.4.n2866